Standigm, a leading workflow AI drug discovery company from South Korea has opened a new office in Cambridge, United Kingdom ("UK"), to accommodate the company's rapid growth in the European market.

Standigm has proprietary technology including AI platforms encompassing novel target identification to novel compound design to generate commercially valuable drug pipelines. The company now collaborates with multiple global partners, including Milner Therapeutics Institute, University of Cambridge.

With its corporate headquarters in Seoul, South Korea, the opening of this new office in Cambridge is consistent with Standigm's growth strategy to deepen its global footprints and it will enable Standigm to have a physical presence in the European market. This office will cover the European region for Standigm, to discover global partners for its target identification research. 

"Our target identification AI platform has proven its innovativeness with a recent growing number of global partners we collaborate with. Opening of our UK office is yet another step towards achieving our goal to make AI drug discovery the standard in the pharmaceutical industry" said Hee Jung Koo, Head of the UK office.